Market Scenario
The global hyperpigmentation disorders treatment market analysis is accounted for USD 3,915 million in 2017 and expected to register 7.1% CAGR during the forecast period (2018–2023).
Hyperpigmentation disorder refers to harmless skin condition that causes darkened skin patches light brown to black in color. It is a common disorder of the skin and melasma is a common cause of facial hyperpigmentation. There are various types of hyperpigmentation, however, few of the most common such as melasma, solar lentigines, and post-inflammatory hyperpigmentation.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7462
The increasing demands for outpatient and minimally invasive
dermabrasion procedures, include augmented adoption of lasers in pigmentation disorders treatment and growing expenditure on the cosmetics across the world are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as new product launches are contributing to the growth of the market. According to the American Society of Plastic Surgeons, the number of dermabrasion cosmetic procedures have increased from 42,218 in 2000 to 88,182 in 2016 with a 109% increase during the estimated period.
The lack of adequate reimbursement policy and high costs involved in the establishment of these centers may hamper the growth of the market during the assessment period.
Key Players
Some of the key players in the global hyperpigmentation disorders treatment market Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Inc., Galderma laboratories (Nestle Skin Health S.A), Obagi Cosmeceuticals LLC, Pierre Fabre, RXi Pharmaceuticals Corporation, SkinCeuticals International, and Vivier Pharma.
Intended Audience
Medical devices manufacturers
Pharmaceutical Companies
Medical devices product distributors and suppliers
Healthcare providers
Research institutes and academic centers
Government associations
Market research and consulting
Market Segmentation
The global hyperpigmentation disorders treatment market has been segmented on the basis of treatment type, disease indication, end-user, and region.
On the basis of treatment type, the market has been classified as topical drugs, chemical peels, microdermabrasion, laser therapy, phototherapy, and others. the market, by disease indication, has been segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. based on end-user, the market has been segmented into hospitals, aesthetic clinics & dermatology centers, and others. The topical drugs segment is expected to hold the largest market share of the hyperpigmentation disorders treatment market, by treatment type, during the forecast period. Also, by disease indication melasma segment register the considerable growth in comparison to other disease indication.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The hyperpigmentation disorders treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European hyperpigmentation disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The hyperpigmentation disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hyperpigmentation disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas market is expected to be the second-largest hyperpigmentation disorders treatment market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, favorable reimbursement policies in American countries are contributing to the growth of the market in this region.
Europe is expected to be the third largest hyperpigmentation disorders treatment market during the forecast period owing to the rising in aging population. Moreover, the government of these countries are more focus to provide best treatment option to their citizen. According to the report published by world health organization, Europe aging population will increase from 14 million in 2016 to 19 million in 2020 and 40 million to 2050.
The market in the Middle East & Africa is expected to account for the smallest share of the global hyperpigmentation disorders treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
The Asia-Pacific are likely to dominate the global hyperpigmentation disorders treatment market owing to the rising awareness of hyperpigmentation disorders, presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, Asia-Pacific is also expected to be the fastest-growing Hyperpigmentation Disorders Treatment market during the forecast period. According to the world bank group, in 2014, China spent 4.96% of gross domestic product (GDP) in healthcare expenditure, whereas in 2015, healthcare expenditure holds 5.32% of GDP. Also, in 2014, India spent 3.63% of GDP on healthcare, however, in 2015 healthcare expenditure holds 3.89% of GDP.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hyperpigmentation-disorders-treatment-market-7462
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Comments